Nilotinib Stada (Nilotinib)

Nilotinib binds to the ATP‑binding site of the BCR‑ABL tyrosine kinase, preventing the enzyme from activating downstream signaling pathways that promote cell division. By blocking this activity, the drug reduces the proliferation of malignant leukemic cells and can also affect related kinases such as KIT and PDGFR.

The specific dose of Nilotinib Stada is determined by the prescribing physician based on the patient’s clinical condition, disease phase, and tolerability. Healthcare professionals adjust the regimen according to approved guidelines and individual response.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy. Patients should discuss reproductive plans with their healthcare provider.

To order Nilotinib Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity than first‑generation agents such as imatinib. It is often chosen for patients who are resistant or intolerant to earlier therapies, providing faster and deeper molecular responses in many cases.

Nilotinib Stada should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid exposing it to extreme temperatures.

Nilotinib Stada is taken orally, usually as a tablet, with a low‑fat meal to improve absorption. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their clinician.

The most serious risks include QT interval prolongation, which can lead to potentially life‑threatening arrhythmias, as well as severe liver toxicity, pancreatitis, and significant hematologic abnormalities such as neutropenia or thrombocytopenia. Regular monitoring is essential.

Patients with a known hypersensitivity to nilotinib or any of its excipients should avoid the product. It is also contraindicated in individuals with a history of prolonged QT interval, uncontrolled cardiac disease, or severe hepatic impairment without close supervision.